BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Savient Pharmaceuticals, Inc. (SVNT) Enters Co-Promotion Agreement With Ferring Pharmaceuticals, Inc. For Nuflexxa; Savient To Establish Sales Force Targeting Rheumatologists Upon Sale Of Global Biologics Manufacturing Business


10/19/2005 5:13:06 PM

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--March 23, 2005--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), announced today that it has signed a definitive agreement with Ferring Pharmaceuticals, Inc., a subsidiary of Ferring B.V., a privately owned specialty biopharmaceutical company, to enter a co-promotion agreement to market Nuflexxa(TM) (1% Sodium Hyaluronate) in the United States. Under the terms of the agreement, which is contingent upon completion of the sale of Savient's global biologics manufacturing business to Ferring B.V. and Ferring International Centre SA, subsidiaries of Ferring Holding SA, Savient will promote Nuflexxa to rheumatologists in the United States. Ferring will focus its promotional efforts for Nuflexxa on the orthopedic surgeon community in the United States and will market Nuflexxa globally to both rheumatologists and orthopedic surgeons. Savient plans to establish a new sales force targeting the rheumatology community for this co-promotion effort. In addition, Savient will contribute financial support to the medical education, training and related advertising and marketing programs to support Nuflexxa through December 31, 2008. In consideration of this investment, Savient will receive 50% of the global revenue of Nuflexxa above agreed upon revenue thresholds. Savient will invest $20 million in its sales force and other marketing contributions over the first two calendar years of the agreement, subject to adjustment if the closing of the sale of Savient's global biologics manufacturing business does not occur on or before July 31, 2005. Beyond the first two calendar years, Savient's continued contribution to and participation in the co-promotion arrangement is contingent upon the achievement of agreed upon revenue thresholds.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->